Latest Breaking News On - Prednisone versus abiraterone acetate - Page 1 : comparemela.com

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®. | April 21, 2023

Region flamandeUnited kingdomCity ofJanssen cilag gmbMartin vogelMagda palhotaPeter lebowitzGerhardt attardJanssen cilag gmUrology care foundationExchange commissionDrug administrationCompanies of johnsonJanssen research developmentEuropean medicines agencyUniversity college london

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology.

United statesSan franciscoStevens johnsonBacilius calmette guerinLuca dezzaniAnia diantonioHans van valenbergKiran patelJanssen biotech incAmerican society of clinical oncologyTesaro incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesJanssen scientific affairs

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoStevens johnsonBacilius calmette guerinLuca dezzaniAnia diantonioHans van valenbergKiran patelJanssen biotech incAmerican society of clinical oncologyTesaro incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesJanssen scientific affairs

Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer

The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of

United statesLaura coughlanGerhardt attardKiran patelMathai mammenZejula smJanssen biotech incTesaro incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonJanssen cilag internationalInternational agency for research on cancerEuropean unionClinical developmentNone of the janssen pharmaceutical companies